Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0D4ZW
|
||||
| Former ID |
DIB003254
|
||||
| Drug Name |
EGS-21
|
||||
| Synonyms |
Glucocerebroside, Enzo; Glucosylceramide, Enzo Biochem
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Crohn's disease [ICD9: 555; ICD10:K50] | Phase 2 | [547959] | ||
| Company |
Enzo Biochem Inc
|
||||
| Formula |
C48H93NO8
|
||||
| Canonical SMILES |
CCCCCCCCCCCCCCCCCCCCCCCC(=O)NC(COC1C(C(C(C(O1)CO)O)O)O)<br />C(C=CCCCCCCCCCCCCC)O
|
||||
| InChI |
1S/C48H93NO8/c1-3-5-7-9-11-13-15-17-18-19-20-21-22-23-24-26-28-30-32-34-36-38-44(52)49-41(40-56-48-47(55)46(54)45(53)43(39-50)57-48)42(51)37-35-33-31-29-27-25-16-14-12-10-8-6-4-2/h35,37,41-43,45-48,50-51,53-55H,3-34,36,38-40H2,1-2H3,(H,49,52)/b37-35+/t41-,42+,43+,45+,46-,47+,48+/m0/s1
|
||||
| InChIKey |
POQRWMRXUOPCLD-GZXCKHLVSA-N
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID | |||||
| Target and Pathway | |||||
| Target(s) | Insulin receptor | Target Info | Modulator | [532546] | |
| KEGG Pathway | Ras signaling pathway | ||||
| Rap1 signaling pathway | |||||
| cGMP-PKG signaling pathway | |||||
| HIF-1 signaling pathway | |||||
| FoxO signaling pathway | |||||
| PI3K-Akt signaling pathway | |||||
| AMPK signaling pathway | |||||
| Adherens junction | |||||
| Insulin signaling pathway | |||||
| Ovarian steroidogenesis | |||||
| Type II diabetes mellitus | |||||
| Non-alcoholic fatty liver disease (NAFLD) | |||||
| Aldosterone-regulated sodium reabsorption | |||||
| NetPath Pathway | TGF_beta_Receptor Signaling Pathway | ||||
| Pathway Interaction Database | Insulin Pathway | ||||
| Signaling events mediated by PTP1B | |||||
| Signaling events mediated by TCPTP | |||||
| Insulin-mediated glucose transport | |||||
| PathWhiz Pathway | Insulin Signalling | ||||
| Leucine Stimulation on Insulin Signaling | |||||
| References | |||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Tang and Dr. Zhang.